Ebglyss features a unique mechanism of action—binding to interleukin-13 with high affinity and a slow dissociation rate

0 SAR
Checkout

Overview

Join Professor Vimal as he delves into the critical role of IL-13 as the dominant cytokine in driving Atopic Dermatitis (AD). In this insightful video, he explains how IL-13’s targeted impact on skin inflammation makes it a pivotal therapeutic target in AD. Discover how Ebglyss, with its selective IL-13 inhibition and unique low dissociation rate, is different from other biologics & effectively managing moderate to severe patients with AD aged 12 and above. Learn how this novel approach offers a new first-line injectable biologic that can deliver long-

This Class for

  • Physician
  • Resident / Fellow

What I will learn?

  • Enhance awareness and clinical understanding among targeted healthcare professionals regarding Atopic Dermatitis (AD) and the differentiated role of Ebglyss (lebrikizumab) in the management of moderate-to-severe AD.

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
    Please go to PDF Material for prescribing information.

    PP-LK-SA-0065

Related Classes